Intellia Therapeutics (NTLA) Q2 2024 earnings summary

Executive summary

• Advanced clinical pipeline with over 150 patients dosed, including NTLA-2002 for HAE, NTLA-2001 for ATTR amyloidosis, and NTLA-3001 for AATD, with multiple programs progressing to pivotal trials and first-in-human studies.

• NTLA-2002 achieved 98% reduction in HAE attacks in Phase II, with most patients attack-free for 18–26 months after a single dose; Phase III to begin in 2H 2024.

• NTLA-2001 Phase III MAGNITUDE trial for cardiomyopathy is enrolling ahead of projections, with global regulatory clearances in over a dozen countries; pivotal trial for polyneuropathy to start by year-end 2024.

• NTLA-3001 received UK regulatory approval for first-in-human study in AATD lung disease, with first patient dosing expected in 2H 2024.

• Strategic collaborations with Regeneron, Sparing Vision, AvenCell, Kyverna, ONK, and ReCode support pipeline advancement.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $939.9 million as of June 30, 2024, down from $1 billion at year-end 2023, supporting operations into late 2026.

• Collaboration revenue was $7 million in Q2 2024, down from $13.6 million in Q2 2023, mainly due to reduced AvenCell license revenue.

• R&D expenses were $114.2 million in Q2 2024, slightly down from $115.3 million in Q2 2023; G&A expenses rose to $31.8 million from $30.7 million.

• Net loss for Q2 2024 was $147.0 million ($1.52/share), compared to $123.7 million ($1.40/share) in Q2 2023.

• $30 million one-time payment received in April 2024 from Regeneron collaboration.

Outlook and guidance

• Cash reserves expected to fund operations into late 2026, with expenses projected to increase as clinical programs advance.

• Phase III trial for NTLA-2002 in HAE to begin in 2H 2024, targeting BLA submission in 2026.

• Pivotal trial for NTLA-2001 in polyneuropathy to start by year-end 2024; rapid enrollment in MAGNITUDE trial for cardiomyopathy continues.

• First patient dosing for NTLA-3001 expected in 2H 2024.

• Updated clinical data from NTLA-2001 and NTLA-2002 to be presented in 2H 2024.